4Q Revenues: €4.3 billion (-23%)
4Q Earnings: €2.3 billion (-28%)
YTD Revenues: €17.3 billion (-9%)
YTD Earnings: €9.3 billion (-8%)
Comments: Results in the quarter and FY reflect lower demand for COVID-19 vaccines. Approximately 2 billion doses of COMIRNATY invoiced in 2022, including approximately 550 million doses of Omicron-adapted bivalent COVID-19 vaccines.
BioNTech expanded its oncology pipeline to 20 programs with 24 ongoing clinical trials including five Phase 2 clinical trials.
R&D expenses were €509.8 million in the quarter, compared to €271.5 million for the comparative prior year period. For the year R&D expenses were €1.5 billion, compared to €949.2 million for the comparative prior year period.